1. NLRP3 inflammasome activation by estrogen promotes the progression of human endometrial cancer
- Author
-
Liu SG, Wu XX, Hua T, Xin XY, Feng DL, Chi SQ, Wang XX, and Wang HB
- Subjects
NLRP3 ,inflammasome ,endometrial cancer ,estrogen ,ERβ ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 - Abstract
Shuang-Ge Liu,1,* Xiao-Xiong Wu,2,* Teng Hua,1,* Xiao-Yan Xin,1 Di-Lu Feng,1 Shu-Qi Chi,1 Xiao-Xiao Wang,1 Hong-Bo Wang11Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China; 2Department of Emergency, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of ChinaCorrespondence: Hong-Bo WangDepartment of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, People’s Republic of ChinaTel +86 1 592 742 7529Fax +86 278 572 6362Email hb_wang1969@sina.com*These authors contributed equally to this workBackground: Activation of NLPR3 inflammasome is associated with the development and progression of some types of malignant tumors, but its role in endometrial cancer is unclear. This study aimed to investigate the expression and function of NLRP3 inflammasome in endometrial cancer. Materials and methods:The expression levels of NLRP3, its inflammasome components and estrogen receptor β in endometrial cancer and paired non-tumor tissues were detected. The effects of NLPR3 silencing or overexpression on the proliferation, migration, and invasion of Ishikawa and HEC-1A cells were determined. The impact of NLPR3 silencing on the growth of implanted tumors was determined in vivo. The effects of estrogen on NLPR3 inflammasome activation and Ishikawa cell proliferation were determined. Results: The upregulation of NLRP3, ASC, caspase-1, and IL-1β was associated with the progression of endometrial cancer and poor survival. NLPR3 silencing inhibited the proliferation, migration, and invasion of endometrial cancer cells while NLPR3 overexpression had opposite effects. NLPR3 silencing reduced IL-1β and caspase-1 expression and the growth of implanted endometrial tumors, accompanied by decreased pro-IL-1β maturation. Estrogen enhanced NLPR3, ERβ, pro-IL-1β, IL-1β expression, and endometrial cancer cell proliferation, which were mitigated by treatment with ERβ inhibitor but not ERα inhibitor. Conclusion: Our results suggest that estrogen acts through ERβ to enhance the activation of NLPR3 inflammasome and promote the progression of endometrial cancer. NLPR3 inflammasome may be a new therapeutic target for endometrial cancer.Keywords: NLRP3, endometrial cancer, estrogen, inflammasome, ER&beta
- Published
- 2019